CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

V. Limmroth, F. Barkhof, N. Desem, M.P. Diamond, G. Tachas

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1780-1788
JournalNeurology
Volume83
Issue number20
DOIs
Publication statusPublished - 2014

Cite this